{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:08:26Z","timestamp":1790140106649,"version":"4.0.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013874.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000}}],"reference-count":255,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013874.pub3","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:28:47Z","timestamp":1741681727000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab for people with multiple sclerosis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Scientific Director's Office; Carlo Besta Foundation and Neurological Institute; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jera","family":"Kruja","sequence":"additional","affiliation":[{"name":"Neurology; UHC Mother Theresa, University of Medicine; Tirana Albania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM); University of Bern; Bern Switzerland"},{"name":"Department of Medical and Surgical Sciences for Children and Adults; University of Modena and Reggio Emilia; Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00415-019-09195-2","article-title":"Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe","volume":"266","author":"Alcal\u00e1","year":"2019","journal-title":"Journal of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1007\/s00415-022-10989-0","article-title":"Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study","volume":"269","author":"Alcal\u00e1","year":"2022","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12913-023-09462-z","article-title":"Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia","volume":"23","author":"Alharbi","year":"2023","journal-title":"BMC Health Service Research"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013874.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0006|cit6","first-page":"36","article-title":"Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab","volume":"24","author":"Alping","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.13936","article-title":"Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis","volume":"26","author":"Boremalm","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0008|cit8","first-page":"323","article-title":"Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis","volume":"23","author":"Salzer","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Cheshmavar M Mirmosayyeb O Badihian N Badihian S Shaygannejad V Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial Acta Neurologica Scandinavica 2021 143 2 178 87","DOI":"10.1111\/ane.13344"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0010|cit10","unstructured":"Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients clinicaltrials.gov\/show\/NCT03315923"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0011|cit11","volume-title":"Serious cardiovascular events among Swedish multiple sclerosis patients treated with rituximab, natalizumab, fingolimod, and dimethyl-fumarate: a nationwide cohort study [Masters thesis]","author":"Cuijpers","year":"2019"},{"issue":"S2","key":"10.1002\/14651858.CD013874.pub3-BIB0012|cit12","first-page":"P644","article-title":"Rate of cardiovascular disease among Swedish multiple sclerosis patients treated with rituximab, natalizumab, fingolimod, and dimethyl fumarate: a nationwide cohort study","volume":"25","author":"Frisell","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0013|cit13","first-page":"484-91","article-title":"Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis","volume":"57","author":"Etemadifar","year":"2019","journal-title":"Acta Medica Iranica"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"205521732096450","DOI":"10.1177\/2055217320964505","article-title":"A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurology"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0017|cit17","unstructured":"A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis clinicaltrials.gov\/show\/NCT00097188"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0018|cit18","first-page":"A254","article-title":"Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial","volume":"72 (11 Suppl 3)","author":"Hawker","year":"2009","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0020|cit20","unstructured":"A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS) clinicaltrials.gov\/show\/NCT00087529"},{"issue":"13","key":"10.1002\/14651858.CD013874.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.3390\/jcm11133584","article-title":"Effect of rituximab compared with natalizumab and fingolimod in patients with relapsing-remitting multiple sclerosis: a cohort study","volume":"11","author":"Hern\u00e1ndez-Preciado","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.autrev.2006.02.012","article-title":"A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study","volume":"5","author":"Gauthier","year":"2006","journal-title":"Autoimmunity Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013874.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e2134627","DOI":"10.1001\/jamanetworkopen.2021.34627","article-title":"Comparison of dimethyl fumarate vs fingolimod and rituximab vs natalizumab for treatment of multiple sclerosis","volume":"4","author":"Hou","year":"2021","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1212\/NXI.0000000000000864","article-title":"Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity","volume":"7","author":"Zhang","year":"2020","journal-title":"Neurology (R) Neuroimmunology & Neuroinflammation"},{"issue":"S2","key":"10.1002\/14651858.CD013874.pub3-BIB0025|cit25","first-page":"912","article-title":"Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS","volume":"25","author":"Kalincik","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0026|cit26","unstructured":"Poster at ECTRIMS 2019 attached to the email [personal communication] Email to: G Filippini"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0028|cit28","unstructured":"Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe) clinicaltrials.gov\/show\/NCT01212094"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/13524585211031128","article-title":"Risk of depression in multiple sclerosis across disease-modifying therapies","volume":"28","author":"Longinetti","year":"2022","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0031|cit31","first-page":"502","article-title":"Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study","volume":"24","author":"Luna","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0032|cit32","unstructured":"Moss BP 6-month Effectiveness, Safety and Tolerability of Ocrelizumab and Comparative Safety with Rituximab [Masters thesis] Cleveland (OH) School of Graduate Studies; Case Western Reserve University https:\/\/etd.ohiolink.edu\/acprod\/odb_etd\/ws\/send_file\/send?accession=case1579784364389245&disposition=inline"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","article-title":"Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis","volume":"76","author":"Naegelin","year":"2019","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"103812","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0035|cit35","unstructured":"The French multiple sclerosis registry clinicaltrials.gov\/show\/NCT02889965"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0036|cit36","unstructured":"The results tables after excluding ocrelizumab of our study [personal communication] Email to: G Filippini"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s13311-022-01202-1","article-title":"Comparative effectiveness of natalizumab versus anti-CD20 in highly active relapsing-remitting multiple sclerosis after fingolimod withdrawal","volume":"19","author":"Rollot","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013874.pub3-BIB0039|cit39","first-page":"O180","article-title":"A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis","volume":"28","author":"Roos","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaneurol.2023.1625","article-title":"Rituximab vs ocrelizumab in relapsing-remitting multiple sclerosis","volume":"80","author":"Roos","year":"2023","journal-title":"JAMA Neurology"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of rituximab relative to IFN-\u03b2 or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry","volume":"24","author":"Spelman","year":"2018","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0042|cit42","unstructured":"RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis \u2013 RIFUND-MS www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-004116-38\/SE"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0043|cit43","unstructured":"RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis (RIFUND-MS) clinicaltrials.gov\/show\/NCT02746744"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/WNL.90.15_supplement.P1.382","article-title":"Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience","volume":"90","author":"Vollmer","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/acn3.51111","article-title":"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment","volume":"7","author":"Vollmer","year":"2020","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","article-title":"Exit strategies in natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study","volume":"18","author":"Zangh\u00ec","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"101980","DOI":"10.1016\/j.msard.2020.101980","article-title":"Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland","volume":"40","author":"Airas","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","article-title":"Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study","volume":"265","author":"Alcal\u00e1","year":"2018","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0050|cit50","first-page":"343","article-title":"Real-life experience with rituximab for the treatment of multiple sclerosis: report from two MS referral centres","volume":"23","author":"Perez Miralles","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/WNF.0000000000000268","article-title":"Safety and efficacy of rituximab: experience of a single multiple sclerosis center","volume":"41","author":"Alldredge","year":"2018","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"205521731562380","DOI":"10.1177\/2055217315623800","article-title":"Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures","volume":"1","author":"Alvarez","year":"2015","journal-title":"Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"},{"issue":"11","key":"10.1002\/14651858.CD013874.pub3-BIB0053|cit53","first-page":"544","article-title":"Assessing the efficacy, tolerability, and safety of rituximab for the treatment of multiple sclerosis: experience in 313 patients at a large academic center","volume":"23","author":"Alvarez","year":"2015","journal-title":"Multiple Sclerosis Journal"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0055|cit55","first-page":"803","article-title":"Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"205521731667210","DOI":"10.1177\/2055217316672100","article-title":"Experience with long-term rituximab use in a multiple sclerosis clinic","volume":"2","author":"Barra","year":"2016","journal-title":"Multiple Sclerosis Journal Experimental, Translational and Clinical"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Bellinvia A Prestipino E Portaccio E Razzolini L Fonderico M Fratangelo R Experience with rituximab therapy in a real-life sample of multiple sclerosis patients Neurological Sciences 2020 41 10 2939 45 10.1007\/s10072-020-04434-1","DOI":"10.1007\/s10072-020-04434-1"},{"issue":"20","key":"10.1002\/14651858.CD013874.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e1893","DOI":"10.1212\/WNL.0000000000006500","article-title":"Intrathecal treatment trial of rituximab in progressive MS: an open-label phase 1b study","volume":"91","author":"Bergman","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0059|cit59","unstructured":"Intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis (ITT-PMS) clinicaltrials.gov\/show\/NCT01719159"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden \u2013 outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.msard.2019.02.013","article-title":"Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement","volume":"30","author":"Bhargava","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"8813498","DOI":"10.1155\/2021\/8813498","article-title":"No early effect of intrathecal rituximab in progressive multiple sclerosis (EFFRITE clinical trial)","volume":"2021","author":"Bonnan","year":"2021","journal-title":"Multiple Sclerosis International"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0063|cit63","unstructured":"Intrathecal rituximab in progressive multiple sclerosis (EFFRITE) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-005493-11\/FR"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0064|cit64","unstructured":"Intrathecal rituximab in progressive multiple sclerosis (EFFRITE) clinicaltrials.gov\/show\/NCT02545959"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013874.pub3-BIB0065|cit65","first-page":"528","article-title":"Discontinuation and dose reduction of rituximab in patients with relapsing remitting multiple sclerosis","volume":"26","author":"Boremalm","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0066|cit66","doi-asserted-by":"crossref","unstructured":"Boremalm M Sundstr\u00f6m P Salzer J Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis Journal of Neurology 2021 268 6 2161 8 10.1007\/s00415-021-10399-8","DOI":"10.1007\/s00415-021-10399-8"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0067|cit67","first-page":"871","article-title":"Adverse events of rituximab in a Swedish MS population sample","volume":"22","author":"Bostr\u00f6m","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11585960-000000000-00000","article-title":"Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre","volume":"34","author":"Brown","year":"2011","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Caldito NG Shirani A Salter A Stuve O Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA Adverse Event Reporting Database Multiple Sclerosis 2021 27 7 1066 76","DOI":"10.1177\/1352458520949986"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0070|cit70","first-page":"180","article-title":"Rituximab in the treatment of multiple sclerosis. Experience of a tertiary care hospital in Mexico","volume":"159","author":"Castro-Mac\u00edas","year":"2023","journal-title":"Gaceta Medica de Mexico"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurology, Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756285612461165","article-title":"Rituximab combination therapy in relapsing multiple sclerosis","volume":"5","author":"Cross","year":"2012","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurology, Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0075|cit75","unstructured":"Switch To RItuXimab in MS. A phase 2 open label study of Rituximab in MS patients previously treated with self-injectables using a target based therapy approach \u2013 STRIX-MS www.clinicaltrialsregister.eu"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","article-title":"Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab","volume":"87","author":"Flon","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/1352458516676643","article-title":"Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS","volume":"23","author":"Flon","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e0192516","DOI":"10.1371\/journal.pone.0192516","article-title":"Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls","volume":"13","author":"Flon","year":"2018","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0079|cit79","volume-title":"Treatment with the monoclonal antibody rituximab in multiple sclerosis [Dissertation for PhD]","author":"Flon","year":"2018"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Disanto G Ripellino P Riccitelli GC Sacco R Scotti B Fucili A De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis Multiple Sclerosis 2021 27 8 1230 9 10.1177\/1352458520952036","DOI":"10.1177\/1352458520952036"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1177\/1352458518772748","article-title":"Efficacy of rituximab in refractory RRMS","volume":"25","author":"Durozard","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2019","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0084|cit84","unstructured":"Switch To RItuXimab in MS extension. An extension study of STRIX-MS \u2013 a phase 2 open label study of Rituximab in MS patients previously treated with self-injectables using a target based therapy approach www.clinicaltrialsregister.eu\/ctr-search\/trial\/2013-002378-26\/results"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0085|cit85","unstructured":"Efficacy of rituximab at low doses in multiple sclerosis \u2013 a prospective, randomized, double-blind, active controlled, pilot trial www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-000426-35\/AT"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0086|cit86","first-page":"96","article-title":"JC titers in multiple sclerosis (MS) patients treated with rituximab, fingolimod and dimethyl fumarate at an American MS center","volume":"23","author":"Gottesman","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013874.pub3-BIB0087|cit87","first-page":"20","article-title":"Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis","volume":"25","author":"Hallberg","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ane.13225","article-title":"Rituximab in multiple sclerosis at general hospital level","volume":"141","author":"Hellgren","year":"2020","journal-title":"Acta Neurologica Scandinavica"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/WNL.0000000000006916","article-title":"Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis","volume":"92","author":"Honce","year":"2019","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0091|cit91","unstructured":"Comparison of rituximab induction therapy followed by glatiramer acetate (GATEWAYII) clinicaltrials.gov\/show\/NCT01569451"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0092|cit92","unstructured":"Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motion en.irct.ir\/trial\/38158"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"101468","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"Suppl 15","DOI":"10.1212\/WNL.92.15_supplement.P4.2-094","article-title":"Anti CD20 therapies and pregnancy in neuroimmunological disorders \u2013 a case series from Germany","volume":"92","author":"Kuempfel","year":"2019","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0095|cit95","first-page":"231830","article-title":"Mortality rates in large US and Swedish rituximab-treated multiple sclerosis cohorts","volume":"24","author":"Langer-Gould","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"S2","key":"10.1002\/14651858.CD013874.pub3-BIB0096|cit96","first-page":"570","article-title":"Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts","volume":"25","author":"Langer-Gould","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"18","key":"10.1002\/14651858.CD013874.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"e1939","DOI":"10.1212\/WNL.0000000000009374","article-title":"Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort","volume":"94","author":"Langer-Gould","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00325481.2019.1649975","article-title":"A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus","volume":"131","author":"Leonidou","year":"2019","journal-title":"Postgraduate Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with Coronavirus disease 2019 and multiple sclerosis","volume":"77","author":"Louapre","year":"2020","journal-title":"JAMA Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013874.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurology and Therapy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013874.pub3-BIB0102|cit102","first-page":"653","article-title":"Rituximab as an effective treatment option after natalizumab withdrawal","volume":"22","author":"Malucchi","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0103|cit103","first-page":"751","article-title":"Rituximab in multiple sclerosis: real world experience from three tertiary care MS centers from southern India","volume":"25","author":"Mathew","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.msard.2020.102210","article-title":"Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country","volume":"43","author":"Mathew","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12031-020-01523-w","article-title":"Effect of rituximab on Expanded Disability Status Scale and relapse rate in multiple sclerosis patients","volume":"70","author":"Mazdeh","year":"2020","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"Journal of Neuroimmunology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013874.pub3-BIB0107|cit107","first-page":"14","article-title":"Rituximab treatment for MS: an observational multicentric dose comparison. Strategies for disease modification","volume":"26","author":"Midaglia","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0108|cit108","first-page":"805","article-title":"The safety and efficacy of rituximab use in secondary progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data","volume":"22","author":"Morales","year":"2016","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013874.pub3-BIB0109|cit109","first-page":"16","article-title":"The safety and efficacy of rituximab use in secondary-progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data","volume":"88","author":"Morales","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756285612461165","article-title":"Rituximab combination therapy in relapsing multiple sclerosis","volume":"5","author":"Cross","year":"2012","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"23","key":"10.1002\/14651858.CD013874.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","article-title":"Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial","volume":"74","author":"Naismith","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/archneurol.2010.99","article-title":"Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis","volume":"67","author":"Piccio","year":"2010","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"101419","DOI":"10.1016\/j.msard.2019.101419","article-title":"Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: an observational study","volume":"36","author":"Naser Moghadasi","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"S2","key":"10.1002\/14651858.CD013874.pub3-BIB0114|cit114","first-page":"775","article-title":"Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions","volume":"25","author":"Alvarez","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0115|cit115","unstructured":"Tolerability and safety of switching from rituximab to ocrelizumab in patients with relapsing forms of multiple sclerosis clinicaltrials.gov\/show\/NCT03979456"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0116|cit116","unstructured":"RItuximab long-term DOSE Trial in Multiple Sclerosis \u2013 RIDOSE-MS www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-000721-31\/SE"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0117|cit117","unstructured":"RItuximab long-term DOSE trial in Multiple Sclerosis \u2013 RIDOSE-MS clinicaltrials.gov\/show\/NCT03979456"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0118|cit118","unstructured":"Rituximab-induced hypogammaglobulinemia in multiple sclerosis clinicaltrials.gov\/show\/NCT04283747"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1352458511418631","article-title":"Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis","volume":"18","author":"Nielsen","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"101982","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0121|cit121","first-page":"117957352211096","article-title":"Alopecia in multiple sclerosis patients treated with disease modifying therapies","volume":"14","author":"Porwal","year":"2022","journal-title":"Journal of Central Nervous System Disease"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"103832","DOI":"10.1016\/j.msard.2022.103832","article-title":"Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis","volume":"63","author":"Porwal","year":"2022","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e903","DOI":"10.1212\/NXI.0000000000000903","article-title":"Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab","volume":"7","author":"Razaz","year":"2020","journal-title":"Neurology (R) Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"102472","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"20","key":"10.1002\/14651858.CD013874.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0126|cit126","doi-asserted-by":"crossref","unstructured":"Schwake C Gold R Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis Neurological Research and Practice 2020 2 30 10.1186\/s42466-020-00074-0","DOI":"10.1186\/s42466-020-00074-0"},{"issue":"5","key":"10.1002\/14651858.CD013874.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"e0197415","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"Plos One"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2169\/internalmedicine.3408-19","article-title":"Treatment with rituximab in the acute phase of relapsing remitting multiple sclerosis","volume":"59","author":"Shima","year":"2020","journal-title":"Internal Medicine (Tokyo, Japan)"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and Coronavirus disease 2019 severity in multiple sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","article-title":"The effects of intrathecal rituximab on biomarkers in multiple sclerosis","volume":"6","author":"Topping","year":"2016","journal-title":"Multiple Sclerosis & Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0132|cit132","doi-asserted-by":"crossref","unstructured":"Torgauten HM Myhr KM Wergeland S B\u00f8 L Aarseth JH Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis \u2013 a cohort study Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical 2021 7 1 2055217320973049 10.1177\/2055217320973049","DOI":"10.1177\/2055217320973049"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013874.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaci.2018.12.051","article-title":"Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents","volume":"143","author":"Tsao","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0134|cit134","first-page":"P4.2","article-title":"Evaluating the tolerability and safety of switching from rituximab to ocrelizumab: infusion related reactions in relapsing forms of multiple sclerosis","volume":"92 (15 Suppl)","author":"Alvarez","year":"2019","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Vollmer BL Wallach AI Corboy JR Dubovskaya K Alvarez E Kister I Serious safety events in rituximab-treated multiple sclerosis and related disorders Annals of Clinical and Translational Neurology 2020 7 9 1477 87 10.1002\/acn3.51136","DOI":"10.1002\/acn3.51136"},{"issue":"10","key":"10.1002\/14651858.CD013874.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"101402","DOI":"10.1016\/j.msard.2019.101402","article-title":"Rituximab-induced serum sickness in multiple sclerosis patients","volume":"36","author":"Wolf","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"9084759","DOI":"10.1155\/2018\/9084759","article-title":"Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study","volume":"2018","author":"Yamout","year":"2018","journal-title":"Journal of Immunology Research"},{"issue":"12","key":"10.1002\/14651858.CD013874.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab: a multicentric Italian-Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0140|cit140","first-page":"935","article-title":"Serious adverse events related to Rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder patients","volume":"24","author":"Zhovtis Ryerson","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013874.pub3-BIB0141|cit141","first-page":"92","article-title":"Comparison of ocrelizumab and rituximab over two years of treatment for multiple sclerosis","volume":"29","author":"Vollmer","year":"2023","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0142|cit142","unstructured":"MultipleMS \u2013 Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002634-24\/SE"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0143|cit143","unstructured":"Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): a randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002981-15\/DK"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0144|cit144","unstructured":"Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis (DanNORMS) clinicaltrials.gov\/ct2\/show\/NCT04688788"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0145|cit145","unstructured":"COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-003587-39\/SE"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0146|cit146","unstructured":"COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS) clinicaltrials.gov\/show\/NCT03193866"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0147|cit147","unstructured":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) clinicaltrials.gov\/show\/NCT03500328"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0148|cit148","unstructured":"Determining the Effectiveness of earLy Intensive Versus Escalation approaches for RRMS (DELIVER-MS) clinicaltrials.gov\/show\/NCT03535298"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0149|cit149","unstructured":"Best available therapy versus autologous hematopoetic stem cell transplant for multiple sclerosis (BEAT-MS) clinicaltrials.gov\/show\/NCT04047628"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0150|cit150","unstructured":"Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001505-24\/NO"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0151|cit151","unstructured":"Norwegian study of oral cladribine and rituximab in multiple sclerosis (NOR-MS) clinicaltrials.gov\/show\/NCT04121403"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013874.pub3-BIB0152|cit152","first-page":"207","article-title":"A prospective randomized open-label blinded endpoint multicenter non-inferiority study of oral cladribine and rituximab in multiple sclerosis (NOR-MS)","volume":"26","author":"Nygaard","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0153|cit153","first-page":"EP1057","article-title":"A Norwegian prospective randomized open-label blinded endpoint multicentre non-inferiority study of oral cladribine and rituximab in multiple sclerosis (NOR-MS)-baseline patient data","volume":"28","author":"Overas","year":"2022","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0154|cit154","unstructured":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) clinicaltrials.gov\/ct2\/show\/NCT04578639"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0155|cit155","unstructured":"A prospective randomized trial of non-inferiority comparing rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis (TRIO) clinicaltrials.gov\/show\/NCT05758831"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0156|cit156","unstructured":"Czech pharmaco-epidemiological real world data study focused on effectiveness of different disease modifying drugs clinicaltrial.gov\/NCT05762003"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0157|cit157","unstructured":"Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS (Noisy Rebels) clinicaltrials.gov\/NCT05834855"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0158|cit158","unstructured":"Montpellier prospective cohort in relapsing remitting multiple sclerosis using imaging and serologic (PROMISE) clinicaltrials.gov\/show\/NCT05962177"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nri2454","article-title":"The who, how and where of antigen presentation to B cells","volume":"9","author":"Batista","year":"2009","journal-title":"Nature Reviews. Immunology"},{"issue":"10","key":"10.1002\/14651858.CD013874.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurology"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"Lancet Haematology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leucoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"Journal of Neurovirology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ane.12963","article-title":"Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden \u2013 outlier or predecessor?","volume":"138","author":"Berntsson","year":"2018","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"International Reviews of Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013874.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"e200152","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurology (R) Neuroimmunology & Neuroinflammation"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Expert Panel of the 27th Annual Meeting of the European Charcot Foundation. Role of B Cells in Multiple Sclerosis and Related Disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"789\u2013807","DOI":"10.1007\/s40273-021-01032-7","article-title":"Economic burden of multiple sclerosis in low- and middle-income countries: a systematic review","volume":"39","author":"Dahham","year":"2021","journal-title":"PharmacoEconomics"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"832","DOI":"10.18553\/jmcp.2020.26.7.832","article-title":"Indications for rituximab use in an integrated health care delivery system","volume":"26","author":"Delate","year":"2020","journal-title":"Journal of Managed Care & Speciality Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD013874.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","article-title":"Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis","volume":"178","author":"Duddy","year":"2007","journal-title":"Journal of Immunology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0172|cit172","unstructured":"European Medicines Agency (EMA) Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. EMA\/CHMP\/771815\/2011, Rev. 2 www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0173|cit173","unstructured":"European Commission Study on off-label use of medicinal products in the European Union ec.europa.eu\/health\/sites\/health\/files\/files\/documents\/2017_02_28_final_study_report_on_off-label_use_.pdf"},{"issue":"5","key":"10.1002\/14651858.CD013874.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0175|cit175","unstructured":"Drugs@FDA: FDA-Approved Drugs www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103705s5460lbl.pdf"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0176|cit176","unstructured":"Filippini G Outcomes for relapsing and progressive multiple sclerosis [personal communication] Email to: E Alvarez"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0177|cit177","unstructured":"Filippini G Outcome for relapsing and progressive multiple sclerosis [personal communication] Email to: P Alping"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0178|cit178","unstructured":"Filippini G Methods, data analysis, and distinct results in the treatment arms [personal communication] Email to: P Frisell"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0179|cit179","unstructured":"Filippini G Methods, patients, outcomes Email to: Fabien Rollot and David Laplaud"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0180|cit180","unstructured":"Filippini G Methods, patients, outcomes Email to: Timothy Vollmer"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0181|cit181","unstructured":"Filippini G Information to judge domains of the ROBINS-I tool Email to: Zongqi Xia"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0182|cit182","unstructured":"Filippini G Was the study conducted and published? Email to: Nazanin Razazian"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0183|cit183","unstructured":"Filippini G Outcomes for relapsing and progressive multiple sclerosis [personal communication] Email to: O Stuve"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0184|cit184","unstructured":"Filippini G Total number of patients treated with fingolimod and those treated with glatiramer Email to: A Langer-Gould"},{"issue":"7","key":"10.1002\/14651858.CD013874.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1352458511433302","article-title":"Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence","volume":"18","author":"Giovannoni","year":"2012","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011381.pub3","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0187|cit187","unstructured":"Limited coverage drugs \u2013 rituximab www2.gov.bc.ca\/gov\/content\/health\/practitioner-professional-resources\/pharmacare\/prescribers\/limited-coverage-drug-program\/limited-coverage-drugs-rituximab"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0188|cit188","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","article-title":"B cell therapy for multiple sclerosis: entering an era","volume":"83","author":"Greenfield","year":"2018","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0191|cit191","unstructured":"Hallberg S Boremalm M Evertsson B Lillvall E Johansson F Lycke J Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis ECTRIMS online library. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2019 Sept 11-13; Stockholm (Sweden) 2019"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1352458514561911","article-title":"The Charcot Lecture: beating MS: a story of B cells, with twists and turns","volume":"21","author":"Hauser","year":"2015","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0193|cit193","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0194|cit194","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0196|cit196","unstructured":"Institute for Clinical and Economic Review (ICER) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: final policy recommendations; 2023 https:\/\/icer.org\/wp-content\/uploads\/2023\/02\/ICER_MS_Policy_Recommendations.pdf"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1352458519858604","article-title":"Rituximab treatment for multiple sclerosis","volume":"26","author":"Ineichen","year":"2020","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD013874.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1474-4422(19)30390-4","article-title":"Essential medicines for patients with multiple sclerosis (Editorial)","volume":"18","year":"2019","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/1352458511431076","article-title":"Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)","volume":"18","author":"Langdon","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/acn3.51326","article-title":"Improving quality, affordability, and equity of multiple sclerosis care","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/13524585211030207","article-title":"Ethical use of off-label disease-modifying therapies for multiple sclerosis","volume":"27","author":"Laurson-Doube","year":"2021","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0204|cit204","unstructured":"Lin GA Whittington MD Nikitin D Agboola F McKenna A Herron-Smith S Treatments for relapsing forms of multiple sclerosis; final evidence report https:\/\/icer.org\/wp-content\/uploads\/2022\/04\/ICER_MS_Final_Evidence_Report_022123.pdf"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD013874.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1590\/0004-282x20180078","article-title":"Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis","volume":"76","author":"Marques","year":"2018","journal-title":"Arquivos de Neuro-psiquiatria"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.msard.2020.102210","article-title":"Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country","volume":"43","author":"Mathew","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/1352458516664210","article-title":"Increased ex vivo antigen presentation profile of B cells in multiple sclerosis","volume":"23","author":"Mathias","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0213|cit213","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Thomas J Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-14-58","article-title":"Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis","volume":"14","author":"Meyer-Moock","year":"2014","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0216|cit216","unstructured":"The Multiple Sclerosis International Federation (MSIF) Atlas of MS, 3rd Edition www.atlasofms.org"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0218|cit218","unstructured":"Norwegian Institute of Public Health Health technology assessment of medicines used for multiple sclerosis - project description www.fhi.no\/en\/projects\/Health-Technology-Assessment-of-medicines-used-for-multiple-sclerosis"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0219|cit219","doi-asserted-by":"crossref","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019","DOI":"10.1002\/9781119536604.ch13"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"205521732110518","DOI":"10.1177\/20552173211051855","article-title":"Multiple Sclerosis International Federation guideline methodology for off-label treatments for multiple sclerosis","volume":"7","author":"Piggott","year":"2021","journal-title":"Multiple Sclerosis Journal - Experimental, Translational and Clinical"},{"issue":"6","key":"10.1002\/14651858.CD013874.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neurol.2019.08.012","article-title":"What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature","volume":"176","author":"Pourcher","year":"2020","journal-title":"Revue Neurologique (Paris)"},{"issue":"17","key":"10.1002\/14651858.CD013874.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013874.pub3-BIB0226|cit226","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013606.pub2","article-title":"Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis","author":"Reeve","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0227|cit227","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0228|cit228","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2021"},{"issue":"8","key":"10.1002\/14651858.CD013874.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD013874.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nature Reviews. Neuroscience"},{"issue":"20","key":"10.1002\/14651858.CD013874.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"e00555","DOI":"10.1002\/prp2.555","article-title":"Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card","volume":"8","author":"Sarsour","year":"2020","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0235|cit235","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook\/archive\/v6.1"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jclinepi.2019.10.015","article-title":"GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles","volume":"118","author":"Skoetz","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.25039","article-title":"Good and bad memories following rituximab therapy","volume":"62","author":"St Clair","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"e200056","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2022","journal-title":"Neurology (R) Neuroimmunology & Neuroinflammation"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1002\/14651858.CD013874.pub3-BIB0242|cit242","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012186.pub2","article-title":"Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis \u2013 insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nature Reviews. Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013874.pub3-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"AB16","DOI":"10.1016\/j.jaci.2018.12.051","article-title":"Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents","volume":"143","author":"Tsao","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0245|cit245","unstructured":"US Department of Health and Human Services Criteria for Adverse Events (CTCAE) v5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"issue":"10","key":"10.1002\/14651858.CD013874.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Long-term safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years","volume":"42","author":"Van Vollenhoven","year":"2015","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD013874.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"11","key":"10.1002\/14651858.CD013874.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden","volume":"177","author":"Wadstrom","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0249|cit249","unstructured":"World Health Organization Model List of Essential Medicines \u2013 23rd List, 2023. In: The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO Expert Committee on the Selection and Use of Essential Medicines, 24 \u2013 28 April 2023 https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02"},{"key":"10.1002\/14651858.CD013874.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"101459","DOI":"10.1016\/j.msard.2019.101459","article-title":"Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines","volume":"37","author":"Yamout","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"10.1002\/14651858.CD013874.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/13524585231205970","article-title":"Disease-modifying therapies enter the World Health Organization Essential Medicines List: a victory now requiring a roadmap of implementation","volume":"30","author":"Yamout","year":"2024","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"issue":"4","key":"10.1002\/14651858.CD013874.pub3-BIB0252|cit252","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1007\/s13311-020-00950-2","article-title":"The pharmacogenetics of rituximab: potential implications for anti-CD20 therapies in multiple sclerosis","volume":"17","author":"Zhong","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD013874.pub3-BIB0253|cit253","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013874","article-title":"Rituximab for people with multiple sclerosis","author":"Filippini","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013874.pub3-BIB0254|cit254","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013874.pub2","article-title":"Rituximab for people with multiple sclerosis","author":"Filippini","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12. Art. No.: C","key":"10.1002\/14651858.CD013874.pub3-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009130.pub3","article-title":"Rituximab for relapsing-remitting multiple sclerosis","author":"He","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:19:11Z","timestamp":1774880351000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013874.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":255,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013874.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}